Clinical trial · Observational
Determining Prognostic Immune Markers in Patients With Ovarian Cancer
NCT03862677CI-TRIAL-00103219IMPrOVErecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epithelial Ovarian Cancer | Ovarian Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients with (suspicion of) primary EOC
- interventionNames
- Other: No intervention
- label
- Patients with recurrent EOC
- interventionNames
- Other: No intervention
Primary outcomes (1)
- measure
- Association between the mMDSC/DC ratio in PBMCs in patients with recurrent EOC before the start of treatment and OS
- timeFrame
- 5 years
Secondary outcomes (28)
- measure
- Association between the mMDSC/DC ratio in PBMCs in patients with recurrent EOC before the start of treatment and PFS
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with (suspicion of) primary or recurrent EOC with an indication for surgery, chemotherapy and/or immunotherapy. * Age ≥18 years. * WHO performance status 0-2. * Accessible for treatment and follow-up. * Written informed consent. Exclusion Criteria: * Other active malignancy in past 5 years prior to entry into the study, except for treated non-melanoma skin cancer. * Any known severe infection like HIV, hepatitis A, B and C. * Receiving immune suppressive treatment. * Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.